What Teva Canada does

Teva Canada Limited is the Canadian operating subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Israel's largest pharmaceutical company and the self-described world's largest generic medicine manufacturer. Founded in 1979 as Novopharm in Toronto and rebranded to Teva Canada following acquisition by Teva Pharmaceutical Industries Ltd. in 2011, the company is headquartered at 30 Novopharm Court, Toronto, with manufacturing operations in Toronto (Scarborough) and Stouffville, Ontario, and a specialty/branded-products office in Montreal (Teva Canada Innovation). It markets four core product categories—generic medicines, specialty medicines, biosimilars, and over-the-counter products—plus specific brands including Ajovy (fremanezumab) for migraine prevention, Seasonique and Seasonale extended-cycle birth control pills, and Copaxone for multiple sclerosis.

The business model is the manufacture and sale of pharmaceutical products (one-time license/transaction per unit) across Canada. Generics carry payment terms of 2% 30 days/net 90 with a $500 minimum order and Teva-prepaid freight; branded specialty products use net 30 terms. Distribution runs through direct pharmacy ordering, wholesale to retail and hospital pharmacies nationwide, and a specialty field sales force covering oncology, neurology, and biosimilars. Customers include healthcare professionals, retail and hospital pharmacies, patients and caregivers (served via Patient Support Programs, the Life Effects platform, and co-pay cards such as the Teva Generics Co-pay Card and ACT Methylphenidate ER Co-pay Card), and pharmaceutical partners for in-licensing in CNS, Pain, Respiratory, Oncology, Biologics, and Biosimilars. Parent-level scale (37,000+ Teva employees globally across 60 countries) and Canadian-specific regulatory expertise—including multiple first-mover Health Canada approvals for complex generics—underpin the competitive position.

Name

Teva Canada

Legal name

Teva Canada Limited

Website

https://tevacanada.com

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Teva Canada Limited is the Canadian subsidiary of Teva Pharmaceutical Industries Ltd., manufacturing and marketing generic, specialty, biosimilar, and OTC pharmaceuticals across Canada from Toronto headquarters and Ontario manufacturing facilities, serving pharmacies, healthcare professionals, and patients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Specialty medicines
• Pharmaceutical manufacturing
• Over-the-counter medicines

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Medicines: Production and sale of generic pharmaceutical medications - the core business of Teva as the world's largest medicine cabinet
2. Specialty Medicines: Sale of innovative specialty pharmaceutical products
3. Biosimilar Medicines: Sale of biosimilar medicines expanding the portfolio to deliver innovative biosimilars
4. Over-the-Counter Products: Sale of OTC products including coughs, allergies, pain relief and more

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Teva Canada manufactures and distributes a portfolio of generic medicines, specialty medicines, biosimilar medicines, and over-the-counter products throughout Canada. The company operates manufacturing facilities in Stouffville and Scarborough (Toronto), Ontario, and markets products through retail and hospital pharmacies, complemented by patient support programs and co-pay financial assistance tools. As the Canadian subsidiary of Teva Pharmaceutical Industries Ltd., it also pursues in-licensing collaborations in CNS, pain, respiratory, oncology, biologics, and biosimilars.

Product overview

Teva Canada operates as the Canadian subsidiary of Teva Pharmaceuticals, the world's largest generic medicine cabinet, offering a multi-category portfolio organized around four core product lines: Generic Medicines (affordable alternatives with proven safety and effectiveness), Specialty Medicines (innovative treatments for complex conditions supported by patient programs), Biosimilar Medicines (expanding biologic access), and Over-the-Counter (OTC) Products (cough, allergy, pain relief without prescription). These core offerings are complemented by patient and caregiver support resources including Life Effects (peer stories and guidance), Patient Support Programs, and financial assistance tools like the Teva Generics Co-pay Card and ACT Methylphenidate ER Co-pay Card. A searchable Product Catalogue serves as the primary discovery platform. Teva Canada also markets specific brand products including Ajovy (fremanezumab, a migraine prevention biologic), Seasonique and Seasonale extended-cycle birth control pills, and has an active pipeline seeking in-licensing or collaboration in CNS, Pain, Respiratory, Oncology, Biologics, and Biosimilars at later clinical stages. The company is a subsidiary of Teva Pharmaceutical Industries Ltd. and leverages the global Teva organization's scale and resources.

Differentiator

Problem solved

Functional benefit

Brands

• Teva Canada Innovation: Brand products and specialty medicines division
• Teva Generics

Products and services

• Generic Medicines Teva Canada's core portfolio of generic pharmaceuticals with proven safety and effectiveness compared to brand-name equivalents, providing affordable alternatives to retail and hospital pharmacies across multiple therapeutic areas.
• Specialty Medicines Innovative specialty pharmaceuticals targeting complex conditions, supported by patient assistance programs and specialized healthcare professional resources.
• Biosimilar Medicines Biosimilar products expanding Teva Canada's portfolio to deliver innovative biologics that patients can trust, expanding access to complex biologic therapies.
• Over-the-Counter (OTC) Products Non-prescription healthcare products including cough, allergy, and pain relief medications available to consumers without a prescription.
• Product Catalogue A comprehensive searchable listing of all medicines currently marketed by Teva Canada, enabling healthcare professionals and pharmacies to find and order specific products.
• Ajovy (fremanezumab) A monoclonal antibody injection for the preventive treatment of migraine in adults, launched by Teva Canada Innovation for the Canadian market.
• Seasonique Extended-cycle combination birth control pill (levonorgestrel/ethinyl estradiol) packaged as a 91-day supply, manufactured by Teva Canada Ltd. (DIN #02346176).
• Seasonale Extended-cycle combination birth control pill similar to Seasonique, also manufactured by Teva Canada Ltd. for the Canadian market.
• Patient Support Programs Programs designed to support patients in accessing specialty medicines, including financial assistance and adherence support to improve treatment outcomes.
• Teva Generics Co-pay Card A co-pay assistance card helping patients reduce out-of-pocket costs for Teva generic medications.
• ACT Methylphenidate ER Co-pay Card A co-pay assistance card for extended-release methylphenidate (ACT Methylphenidate ER), helping patients afford ADHD treatment.
• Life Effects A patient support platform featuring real stories, tips, and lived experiences from patients and caregivers to help navigate chronic illness and the healthcare journey.

Quantifiable outcome

• Nearly 200 million people worldwide use Teva medications
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Health Products Stewardship Association (HPSA)coreStrategic or Co-development PartnerTeva Canada supports the Health Products Stewardship Association (HPSA) which manages Medications Return Programs and Sharps Collection Programs, providing safe and convenient disposal of unused or expired household medications in an environmentally responsible manner.
• Prospective Licensing and Collaboration PartnerscoreStrategic or Co-development PartnerTeva Canada seeks in-licensing or collaborative opportunities in later-stage clinical development in therapeutic areas including CNS, Pain, Respiratory, Oncology, Biologics, and Biosimilars. The company leverages mutual R&D and commercial capabilities with partners.
• Femmes Leader en Pharma (Women Leaders in Pharma)minorGTM or Marketing PartnerTeva Canada is a Gold sponsor of Femmes Leader en Pharma, an organization helping women reach their full potential in the pharmaceutical industry, developing a valuable partnership with Canada's leading women's organization in the pharmaceutical sector.
• Centraide/United WayminorOthersTeva Canada supports the Centraide/United Way campaign, with employees helping to fund community programs that have impacted over 2 million people with housing, food, connection, and safety.
• Pride at Work CanadaminorOthersTeva Canada partners with Pride at Work Canada to promote 2SLGBTQIA+ inclusion, celebrating Pride throughout the year through conferences, marches, and events.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Pfizer Canada: Pfizer Canada is a broad incumbent offering innovative biologics and legacy generics; it overlaps with Teva Canada in biosimilars and in CNS, pain and infectious disease categories where Teva competes via in-licensing.
• Novartis Pharmaceuticals Canada: Novartis Canada, through its Sandoz division and innovative medicines business, competes with Teva Canada across both generics/biosimilars and specialty CNS and oncology prescriptions in Canada.

Direct peers

• Apotex Inc. Apotex is the largest Canadian-headquartered generic pharmaceutical manufacturer with deep Canadian distribution and a large generic portfolio directly overlapping Teva Canada's core generic and OTC business.
• Sun Pharma Canada: Sun Pharma's Canadian operations, built on the former Ranbaxy franchise, market generic and specialty products in the same Canadian therapeutic areas Teva Canada serves, including CNS and dermatology.
• JAMP Pharma Group: JAMP Pharma is a Canadian-owned generic pharmaceutical company that has aggressively expanded into biosimilars and specialty generics, bidding directly against Teva Canada on national formulary contracts.
• Auro Pharma Canada: Aurobindo's Canadian generic pharmaceutical subsidiary supplies a broad portfolio of oral and injectable generics in Canada, bidding against Teva Canada in provincial and retail pharmacy channels.
• Viatris Canada: Viatris (formed from Mylan and Pfizer's Upjohn) operates a sizeable Canadian generics franchise spanning oral solids, injectables and biosimilars, going head-to-head with Teva Canada on the same tender panels and product sets.
• Sandoz Canada: Sandoz Canada is the Canadian arm of the world's largest pure-play generics/biosimilars company and competes head-to-head with Teva Canada on provincial formularies, hospital tendering and biosimilar launches.
• Pharmascience Inc. Pharmascience is a privately owned Montreal-based generic pharmaceutical manufacturer with national Canadian distribution, competing directly on the same molecule categories as Teva Canada.

Emerging players

• Amgen Canada: Amgen's Canadian arm serves as both a biologics originator and a biosimilar supplier in therapeutic areas overlapping Teva Canada's specialty/biosimilar business (oncology, bone health, immunology).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/teva-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Canada